In the midst of growing concerns that patients with cancer have limited access to the COVID-19 vaccines, the Association for Clinical Oncology (ASCO) and American Cancer Society Cancer Action Network (ACS CAN), advocacy affiliate of the American Cancer Society, today issued a joint letter to every state governor in the United States urging them to prioritize patients with cancer in the distribution of COVID-19 vaccines in accordance with U.S. Centers for Disease Control and Prevention (CDC) guidelines.
The American Society of Clinical Oncology (ASCO) and Friends of Cancer Research (Friends) jointly issued new recommendations to further efforts to broaden eligibility criteria in cancer clinical trials with the goal of making clinical trials more accessible to patients. The joint recommendations are detailed in a series of articles published in Clinical Cancer Research, a journal of the American Association for Cancer Research. The series provides a comprehensive examination of eligibility criteria for cancer clinical trials with recommendations to address five specific areas: treatment washout periods, concomitant medications, prior therapies, laboratory reference ranges and test intervals, and patient performance status.
The Association for Clinical Oncology (ASCO) applauds the decision by the U.S. District Court for the District of Maryland to grant a temporary restraining order on the implementation of the Most Favored Nation (MFN) Interim Final Rule. Judge Blake’s decision delays the model’s implementation for 14 days while she considers a preliminary injunction, which would further delay the model. The decision notes that there is likely to be irreparable harm if the rule goes into effect January 1, suggesting that the preliminary injunction will likely be granted.
The American Society of Clinical Oncology (the Society), an affiliated organization of the Association for Clinical Oncology (the Association), collectively known as ASCO, submitted an amicus curiae brief in support of motions in four cases to enjoin the Most Favored Nation (MFN) Model from taking effect on January 1, 2021. The Society’s friend-of-the-court brief urges the courts to stop implementation of the model, citing its devastating impact on patients.
ASCO today issued comprehensive recommendations to guide the cancer community’s eventual recovery from the COVID-19 pandemic. By applying lessons learned during the pandemic, ASCO’s Road to Recovery Report: Learning from the COVID-19 Experience to Improve Clinical Research and Cancer Care intends to make cancer care and research opportunities more accessible to and equitable for patients in every community. Importantly, ASCO aims, with its recommendations, to address long-standing cancer care disparities that have been highlighted by the pandemic.
The American Society of Clinical Oncology released today a position statement that recommends specific actions for applying telemedicine in cancer care during the pandenic and after its expiration.
One of the nation’s leading cancer organizations today called for new actions to reduce disparities in cancer outcomes affecting racial and ethnic minorities, rural populations, sexual and gender minorities, people without insurance, and other disadvantaged populations. In a policy statement published in the Journal of Clinical Oncology (JCO), the American Society of Clinical Oncology (ASCO) argues that while progress has been made in raising awareness of disparities and driving research, the cancer community needs to take bolder, more aggressive steps to achieve equity for all patients.
The American Society of Clinical Oncology (ASCO) released a position statement that raises concerns about home infusion of anticancer therapy and Centers for Medicare & Medicaid Services (CMS) regulations regarding the practice.
The American Society of Clinical Oncology (ASCO) and Association of Community Cancer Centers (ACCC) today announced a new collaboration to foster participation in cancer treatment trials to more fully reflect the diversity of people at risk for or living with cancer.
The American Society of Clinical Oncology (the Society) and its affiliate organization the Association for Clinical Oncology (the Association) today announced the results of a survey that tracked the initial impact of the COVID-19 pandemic on cancer clinical trials, highlighted a new research initiative to address the data gap on the coronavirus’ effect on individuals with cancer, and set forth a road to recovery as the cancer care delivery system prepares for life after COVID-19.
“We commend the U.S. Food and Drug Administration (FDA) for releasing draft guidance to encourage the inclusion of older adults in clinical trials of drugs for the treatment of cancer. We thank Richard Pazdur, MD, director of the FDA Oncology Center of Excellence, for his leadership on this important issue.
ALEXANDRIA, Va. — The American Society of Clinical Oncology (ASCO) today released a position statement on state drug repository programs, outlining ASCO’s support for drug repository programs solely for oral medications provided they are maintained within a closed system. The Society also makes recommendations to help ensure that these programs are implemented appropriately, with sufficient patient protections in place.
ALEXANDRIA, Va. -- Today, 106 organizations representing patients, providers, medical researchers, survivors, and families joined together to urge Congress to include the bipartisan CLINICAL TREATMENT Act (H.R. 913) in the upcoming ‘must pass’ healthcare extenders package, which is expected to pass this spring.
“The American Society of Clinical Oncology (ASCO) applauds the Centers for Medicare & Medicaid Services (CMS) for reflecting recommendations in the Society’s position statement on pharmacy benefit managers (PBMs) in the agency’s 2021 and 2022 Medicare Advantage and Part D proposed rule.
Alexandria, Va. – The American Society of Clinical Oncology (ASCO) released a position statement, “Block Grants in Medicaid & Their Impact on Cancer Care,” summarizing the Society’s concerns about the potential negative impact that recent proposals to establish annual limits on federal funding for Medicaid—or block grants—could have on patients with cancer. The statement urges state and federal policymakers not to enact, apply for, or advance any proposals to establish block grants for Medicaid programs.